Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin for Prevention of COVID-19 in Health Personnel
NCT04527211Phase 3Unknown
- Sponsor
- Pontificia Universidad Javeriana
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of CHILD-IVITAB in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Pontificia Universidad Javeriana. Primary endpoint: Clinical development of covid-19 disease during the intervention period at 8 weeks. Status: unknown.
02
Drugs
CHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04527211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527211.